Fat compartments and apolipoprotein B-100 kinetics in overweight-obese men

Obesity Research

Volumn 11, Issue 1, 2003, Pages 152-159

  Watts, Gerald F ^a,d   Chan, Dick C ^a   Barrett, P Hugh R ^a   Susekov, Andrei V ^a,c   Hua, Jianmin ^b   Song, Swithin ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c Myasnikow Institute of Cardiology   (Russian Federation)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Apolipoprotein B 100; Hepatic secretion; Insulin resistance; Intraperitoneal fat

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B100; CARBON; DIAGNOSTIC AGENT; FATTY ACID; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ADULT; ARTICLE; BLOOD; BODY COMPOSITION; DIABETES MELLITUS; DIET; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HOMEOSTASIS; HUMAN; IMPEDANCE; INSULIN RESISTANCE; KINETICS; LIVER; MALE; MASS FRAGMENTOGRAPHY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATHOPHYSIOLOGY; REGRESSION ANALYSIS; SECRETION;

ADIPOSE TISSUE; ADULT; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; BLOOD GLUCOSE; BODY COMPOSITION; CARBON ISOTOPES; DIABETES MELLITUS; DIET; ELECTRIC IMPEDANCE; FATTY ACIDS, NONESTERIFIED; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLUCOSE INTOLERANCE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; KINETICS; LIPOPROTEINS, VLDL; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OBESITY; REGRESSION ANALYSIS;

EID: 0038749549     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2003.24     Document Type: Article

References (43)

1. Déspres JP, Moorjani S, Lupien PJ, et al. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Atherosclerosis. 1990;10:497-511.
2. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjöström L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J. 1984;289:1257-61.
3. Garg A. The role of body fat distribution in insulin resistance. In: Reaven GM, Laws A, eds. Contemporary Endocrinology: Insulin Resistance. Totowa, NJ: Human Press; 1999, pp. 83-96.
4. Björntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis. 1990;10:493-6.
5. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism. 1987;36:54-9.
6. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest. 1995;96:88-98.
7. Caprio S, Hyman LD, Limb C, et al. Central adiposity and its metabolic correlates in obese adolescent girls. Am J Physiol. 1995;269:E118-E26.
8. Packard CJ. Understanding coronary heart disease as a consequence of detective regulation of apolipoprotein B metabolism. Curr Opin Lipidol. 1999; 10: 237-44.
9. Kesaniemi YA, Beltz WF, Grundy SM. Comparisons of metabolism of apolipoprotein B in normal subjects, obese patients, and patients with coronary heart disease. J Clin Invest. 1985;76:586-95.
10. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation. 1996;94:273-8.
11. Thompson GR, Naoumova R, Watts GF. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res. 1996;37:439-47.
12. Sniderman AD, Cianflone K. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler Thromb Vasc Biol. 1993;13:629-36.
13. Watts GF, Cummings MH, Keel JM, et al. Acute hyperinsulinemia decreases hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in normolipidaemic, non-diabetic subjects. Endocrinol Metab. 1996;3:253-63.
14. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest. 1995;95:158-66.
15. Watts GF, Riches FM, Kelly JM, Powell MA, Croft KD. Determinants of the kinetics of very low-density lipoprotein apolipoprotein B-100 in non-obese men. Clin Exp Pharmacol Physiol. 1997;24:556-62.
16. Riches FM, Watts GF, Naoumova RP, et al. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int J Obes Relat Metab Disord. 1998;22:414-23.
17. Watts GF, Riches FM, Humphries SE, et al. Genotypic associations of the hepatic secretion of VLDL apolipoprotein B-100 in obesity. J Lipid Res. 2000;41:481-8.
18. Riches FM, Watts GF, Hua J, et al. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab. 1999;84:2854-61.
19. Carlson LA, Hallberg D. Basal lipolysis and effects of norepinephrine and prostaglandin E on lipolysis in human subcutaneous and omental adipose tissue. J Lab Clin Med. 1968;71:368-77.
20. Carlson LA, Hallberg D, Micheli H. Quantitative studies on the lipolytic response of human subcutaneous and omental adipose tissue to noradrenaline and theophylline. Acta Med Scand. 1969;185:465-9.
21. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
22. Deurenberg P, Yap M. The assessment of obesity: methods for measuring body fat and global prevalence of obesity. Bailliere Clin Endocrinol Metab. 1999;13:1-11.
23. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Adams-Huet B, Grundy SM. Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM. Diabetes. 1996;45:1684-93.
24. Watts GF, Herrmann S, Riches FM. Effects of diet and serotonergic agonist on hepatic apolipoprotein B-100 secretion and endothelial function in obese men. QJM. 2000; 93:153-61.
25. Segal KR, Van Loan M, Fritzgerald PI. Lean body mass estimation by bioelectrical impedance analysis. A four-site cross-validation study. Am J Clin Nutr. 1998;47:7-14.
26. Lukaski HC, Johnson PE, Bolonchuk WW, Lykken GI. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nntr. 1985;41:810-7.
27. Ross R, Leger L, Morris D, de Guise J, Guardo R. Quantification of adipose tissue by MRI: relationship with anthropometric variables. J Appl Physiol. 1992;72:787-95.
28. Cummings MH, Watts GF, Lumb PJ, et al. Comparison of immunoturbidimetric and Lowry methods for measuring concentration of very low density lipoprotein apolipoprotein B-100 in plasma. J Clin Pathol. 1994;47:176-8.
29. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2000;23:S4-S19.
30. Bonora E, Del Prato S, Bonadonna RC, et al. Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women. Diabetes. 1992;41:1151-9.
31. Malmstrom R, Packard CJ, Watson TD et al. Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol. 1997;17:1454-64.
32. Kissebah AH, Alfarsi S, Adams PW, Wynn V. Role of insulin resistance in adipose tissue and liver in the pathogenesis of endogenous hypertriglyceridaemia in man. Diabetologia. 1976;12:563-71.
33. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest. 1983;72:1737-47.
34. Peiris AN, Mueller RA, Smith GA, Struve MF, Kissebah AH. Splanchnic insulin metabolism in obesity. Influence of body fat distribution. J Clin Invest. 1986;78:1648-57.
35. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev. 1994;74:761-811.
36. Bolinder J, Kager L, Ostman J, Arner P. Differences at the receptor and postreceptor levels between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis. Diabetes. 1983;32:117-23.
37. Smith U, Hammersten J, Björntorp P, Kral JG. Regional differences and effect of weight reduction on human fat cell metabolism. Eur J Clin Invest. 1979;9:327-32.
38. Ostman J, Arner P, Engfeldt P, Kager L. Regional differences in the control of lipolysis in human adipose tissue. Metabolism. 1979;28:1198-205.
39. Maheux P, Azhar S, Kern PA, Chen YD, Reaven GM. Relationship between insulin-mediated glucose disposal and regulation of plasma and adipose tissue lipoprotein lipase. Diabetologia. 1997;40:850-8.
40. Laws A. Insulin and dyslipidaemia: implications for coronary heart disease risk. In: Reaven GM, Laws A, eds. Contemporary Endocrinology: Insulin Rsistance. Totowa, NJ: Human Press; 1999, pp. 267-280.
41. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest. 1990;85:1844-52.
42. Misra A, Garg A, Abate N, Peshock RM, Stray-Gundersen J, Grundy SM. Relationship of anterior and posterior subcutaneous abdominal fat to insulin sensitivity in nondiabetic men. Obes Res. 1997;5:93-9.
43. Lithell H, Schele R, Vessby B, Jacobs I. Lipoproteins, lipoprotein lipase, and glycogen after prolonged physical activity. J Appl Physiol. 1984;57:698-702.